CTtrials site

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl
Posts: 367
Joined: Wed Dec 09, 2015 12:12 am

CTtrials site

Post by biopearl » Thu Jun 23, 2016 10:08 pm

Both Janssen trials updated yesterday. bp

Fishermangents
Site Admin
Posts: 529
Joined: Thu Dec 03, 2015 3:39 pm

Re: CTtrials site

Post by Fishermangents » Fri Jun 24, 2016 10:21 am

Very interesting! There are some changes to the protocol of IMerge. They skipped the following sentence completely: "../.. in transfusion-dependent participants with low or intermediate-1 risk MDS that is relapsed/refractory to ESA treatment.".

The following sentence has been removed too:
"phase (until disease progression, or unacceptable toxicity, or withdrawal of consent, or lack of response)".

I consider these changes in the protocol as an important sign that they have good reasons for making imetelstat available to the a broader group of MDS patients population. That can only be based on a certain level of success so far and with the consent of the FDA.

Post Reply